| Original language | English (US) |
|---|---|
| Pages (from-to) | 2100-2102 |
| Number of pages | 3 |
| Journal | Gut |
| Volume | 68 |
| Issue number | 11 |
| DOIs | |
| State | Published - 2019 |
Keywords
- histopathology
- ulcerative colitis
ASJC Scopus subject areas
- Gastroenterology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Gut, Vol. 68, No. 11, 2019, p. 2100-2102.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Definitions of response and remission for the Robarts Histopathology Index
AU - Pai, Rish K.
AU - Khanna, Reena
AU - D'Haens, Geert R.
AU - Sandborn, William J.
AU - Jeyarajah, Jenny
AU - Feagan, Brian G.
AU - Vande Casteele, Niels
AU - Jairath, Vipul
N1 - Funding Information: Competing interests rKP has received consulting fees from seres therapeutics, eli Lilly, Protagonist and Genentech outside the submitted work. rK reports fees from Janssen, AbbVie, shire, Pfizer and takeda Canada and from robarts Clinical trials outside the submitted work. GrD reports consulting fees from robarts Clinical trials; personal fees from Ablynx, Amakem, Amgen, AM Pharma, Boehringer-Ingelheim, Bristol Myers squibb, Cosmo, Celgene, Celtrion, Covidien, engene, Galapagos, Medimetrics, Mundipharma, Mitsubishi, Novonordisk, Pfizer, receptos, salix, sandoz, setpoint, shire, teva, tigenix, topivert, Versant and Vifor; grants and personal fees from Abbvie, Ferring, Glaxo smith Kline, Jansen Biologics, Hospira, Merck sharp Dome, Prometheus Labs, robarts Clinical trials, takeda and tillotts; and grants from Falk Pharma and Photopill, outside the submitted work. WJs reports consulting fees from University of Western Ontario (previous owner of robarts Clinical trials), Abbvie, Akros Pharma, Allergan, Ambrx, Amgen, Ardelyx, Arena Pharmaceuticals, Atlantic Pharmaceuticals, Avaxia, Biogen, Boehringer-Ingelheim, Bristol Meyers squibb, Celgene, Conatus, Cosmo technologies, escalier Biosciences, Ferring, Ferring research Institute, Forward Pharma, Galapagos, Genentech, Gilead sciences, Immune Pharmaceuticals,
PY - 2019
Y1 - 2019
KW - histopathology
KW - ulcerative colitis
UR - http://www.scopus.com/inward/record.url?scp=85055883872&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85055883872&partnerID=8YFLogxK
U2 - 10.1136/gutjnl-2018-317547
DO - 10.1136/gutjnl-2018-317547
M3 - Letter
C2 - 30366909
AN - SCOPUS:85055883872
SN - 0017-5749
VL - 68
SP - 2100
EP - 2102
JO - Gut
JF - Gut
IS - 11
ER -